Hematology Oncology Associates of Fredericksburg Inc

Summary

Hematology Oncology Associates of Fredericksburg Inc is a medical facility located in Fredericksburg, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Hematology Oncology Associates of Fredericksburg Inc is involved with conducting 65 clinical trials across 116 conditions. There are 8 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Khalid Matin, and Masey M. Ross.

Top PIs

Clinical Trials running at Hematology Oncology Associates of Fredericksburg Inc

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Non-Small Cell Lung Cancer

Multiple Myeloma

Follicular Lymphoma

Colorectal Cancer

Melanoma

Pancreatic Cancer

BNT327 + Chemotherapy

for Small Cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Recruiting

2 awards

Phase 3

4 criteria

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria